ZYME vs RXRX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 12, 2026

ZYME

37.1
AI Score
VS
RXRX Wins

RXRX

44.1
AI Score

Investment Advisor Scores

ZYME

37score
Recommendation
SELL

RXRX

44score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric ZYME RXRX Winner
Revenue 7.00M 14.14M RXRX
Net Income -89.18M -248.51M ZYME
Net Margin -1274.4% -1757.1% ZYME
Operating Income -89.30M -263.47M ZYME
ROE -111.0% -27.2% RXRX
ROA -22.5% -20.5% RXRX
Total Assets 396.96M 1.21B RXRX
Cash 179.41M 545.68M RXRX
Current Ratio 6.32 5.03 ZYME
Free Cash Flow -77.88M -187.35M ZYME

Relative Price Performance (Last 90 Days)

ZYME 1M: +5.3% · 3M: +14.3% RXRX 1M: -2.7% · 3M: +1.6%

Current Technical Phase

ZYME

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 45

RSI (14): 45.5 · Price: $26.24

RXRX

Distribution
Trim / tighten stop

Price near a flattening SMA50 (slope 0.1%) with fading momentum, RSI 46

RSI (14): 45.6 · Price: $3.20

Fundamentals Snapshot

Metric ZYME RXRX
Market Cap
Forward P/E 22.5 -3.6
Trailing P/E
Revenue (TTM)
Revenue Growth -0.9% -0.6%
Gross Margin -2.5% -7.2%
Operating Margin -9.2% -17.6%
EPS -2.02 -0.98
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, RXRX is currently the stronger investment candidate, winning 5 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.